AbbVie files Item 2.02 8-K; Q3 2025 results in Exhibit 99.1

Rhea-AI Filing Summary

AbbVie Inc. (ABBV) filed an 8-K announcing Q3 2025 results. The company issued a press release for the third quarter ended September 30, 2025, and furnished it with this report.

The press release is included as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition). No financial figures are detailed in this report itself.

0001551152false00015511522025-10-312025-10-310001551152us-gaap:CommonStockMemberexch:XNYS2025-10-312025-10-310001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2025-10-312025-10-310001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2025-10-312025-10-310001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2025-10-312025-10-310001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2025-10-312025-10-310001551152abbv:Sec1.250SeniorNotesdue2031Memberexch:XNYS2025-10-312025-10-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 _____________________________________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 31, 2025

ABBVIE INC.

(Exact name of registrant as specified in its charter)

Delaware

001-35565

32-0375147

(State or other Jurisdiction

(Commission File Number)

(IRS Employer

of Incorporation)

Identification No.)

 _____________________________________________________

1 North Waukegan Road

North Chicago, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.01 Par Value

ABBV

New York Stock Exchange

NYSE Texas

0.750% Senior Notes due 2027

ABBV27

New York Stock Exchange

2.125% Senior Notes due 2028

ABBV28

New York Stock Exchange

2.625% Senior Notes due 2028

ABBV28B

New York Stock Exchange

2.125% Senior Notes due 2029

ABBV29

New York Stock Exchange

1.250% Senior Notes due 2031

ABBV31

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐   

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   

Item 2.02  Results of Operations and Financial Condition

On October 31, 2025, AbbVie Inc. issued a press release announcing financial results for the third quarter ended September 30, 2025.  A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.						Exhibit
99.1						Press Release dated October 31, 2025 (furnished pursuant to Item 2.02).
104						The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

									ABBVIE INC.
Date:			October 31, 2025			By:			/s/ Scott T. Reents
									Scott T. Reents
									Executive Vice President,
									Chief Financial Officer

FAQ

What did AbbVie (ABBV) disclose in its latest 8-K?

AbbVie furnished a press release announcing financial results for the third quarter ended September 30, 2025, under Item 2.02.

When did AbbVie issue the press release for Q3 2025 results?

On October 31, 2025.

Where can I find AbbVie’s Q3 2025 results within the 8-K?

They are provided in the press release furnished as Exhibit 99.1.

Which item of the 8-K covers AbbVie’s results disclosure?

Item 2.02, Results of Operations and Financial Condition.

What period does AbbVie’s Q3 2025 report cover?

The quarter ended September 30, 2025.

Is the press release part of the 8-K exhibits?

Yes, it is furnished as Exhibit 99.1.